EUVIMEDEUVIMED entdecken
Multizentrische Studie

Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study

Julie Litovsky, Florence Hacard, Florence Tétart, Isabelle Boccon-Gibod, Angèle Soria, Delphine Staumont-Sallé, Marie-Sylvie Doutre, Emmanuelle Amsler, Catherine Mansard, Frédéric Dezoteux, Anne-Sophie Darrigade, Brigitte Milpied und 10 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2023-12 · 11 (12) · 3752-3762.e2

DOI: 10.1016/j.jaip.2023.08.033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-12. Verfasst von Julie Litovsky und 21 weiteren Autor:innen. Beteiligte Einrichtung: Département de Dermatologie, C.H.U de Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Urticaria, Chronic Urticaria. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsUrticariaChronic UrticariaHumansOmalizumabRetrospective StudiesQuality of LifeChronic DiseaseChronic Inducible UrticariaTreatment Outcome

Stichwörter der Autor:innen

Chronic urticariaDrug survivalOmalizumabReal-life study

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Département de Dermatologie, C.H.U de Montpellier, Montpellier, France.
  • Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Allergologie et Immunologie Clinique, Pierre Bénite, France.
  • Centre Erik Satie-Allergologie, Rouen University Hospital, Rouen, France.
  • Service de Médecine Interne, Centre National de Référence des Angioedèmes, CHU de Grenoble, Échirolles, France.
  • Service de Dermatologie et Allergologie, Hôpital Tenon AP-HP, Sorbonne Université, Paris, France.
  • CHU Lille, Service de Dermatologie, Université de Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France.

Förderung

  • AstraZeneca

Zitieren

APA

Litovsky, J., Hacard, F., Tétart, F., Boccon-Gibod, I., Soria, A., Staumont-Sallé, D., Doutre, M. S., Amsler, E., Mansard, C., Dezoteux, F., Darrigade, A. S., Milpied, B., Bernier, C., Perrot, J. L., Raison-Peyron, N., Paryl, M., Droitcourt, C., Demoly, P., Grosjean, J., …, & Urticaria Study Group of French Dermatology Society (2023). Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study. The Journal of Allergy and Clinical Immunology: In Practice, 11(12), 3752-3762.e2. https://doi.org/10.1016/j.jaip.2023.08.033

Vancouver

Litovsky J, Hacard F, Tétart F, Boccon-Gibod I, Soria A, Staumont-Sallé D, et al. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(12):3752-3762.e2. doi:10.1016/j.jaip.2023.08.033

BibTeX
@article{Litovsky2023,
  author = {Litovsky, Julie and Hacard, Florence and Tétart, Florence and Boccon-Gibod, Isabelle and Soria, Angèle and Staumont-Sallé, Delphine and Doutre, Marie-Sylvie and Amsler, Emmanuelle and Mansard, Catherine and Dezoteux, Frédéric and Darrigade, Anne-Sophie and Milpied, Brigitte and Bernier, Claire and Perrot, Jean-Luc and Raison-Peyron, Nadia and Paryl, Marie and Droitcourt, Catherine and Demoly, Pascal and Grosjean, Julien and Mura, Thibault and Du-Thanh, Aurélie and Urticaria Study Group of French Dermatology Society, Urticaria Study Group of French Dermatology Society},
  title = {Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  volume = {11},
  number = {12},
  pages = {3752--3762.e2},
  doi = {10.1016/j.jaip.2023.08.033}
}
Kostenlos starten →